Role of antiplatelet therapy in cardiovascular disease III: Peripheral arterial disease

Current Medical Research and Opinion

Volumn 20, Issue 11, 2004, Pages 1851-1855

  Cavendish, Jeffrey J ^a   Safani, Michael ^b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Antiplatelet; Claudication; Cross risk; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; HEPARIN; TIROFIBAN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARM DISEASE; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CASE REPORT; CLAUDICATION; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ILIAC ARTERY OBSTRUCTION; LEG ARTERY; LERICHE SYNDROME; LIFESTYLE; LIMB AMPUTATION; MALE; OCCLUSIVE CEREBROVASCULAR DISEASE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; RISK FACTOR; SMOKING; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

AGED; AGED, 80 AND OVER; ARTERIOSCLEROSIS; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 10044266402     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X10683     Document Type: Article

References (19)

1. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Report available online at: http://www. americanheart.org/downloadable/ heart/1079736729696HDSSt ats2004UpdateREV3-19-04.pdf [accessed 1 Sept 2004]
2. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43
3. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999;47:1255-6
4. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6
5. Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992;49:857-63
6. Becker GJ, McClenny TE, Kovacs ME, et al. The importance of increasing public and physician awareness of peripheral arterial disease. J Vasc Interv Radiol 2002;13:7-11
7. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24
8. Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884-92
9. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995;274:975-80
10. Regensteiner JG, Ware Jr JE, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002;50:1939-46
11. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001;88:787-800
12. Peripheral Arterial Diseases Antiplatelet Consensus Group. Antiplatelet therapy in peripheral arterial disease. Consensus statement. Eur J Vasc Endovasc Surg 2003;26:1-16
13. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990;227:301-8
14. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
15. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39
16. Cavendish JJ, Fugit RV, Safani M. Role of antiplatelet therapy in cardiovascular disease I: acute coronary syndromes. Curr Med Res Opin 2004;20(11):1839-43
17. Cavendish JJ, Cramer SC, Graham GD. Role of antiplatelet therapy in cardiovascular disease II: Ischemic stroke. Curr Med Res Opin 2004;20:1845-9
18. Zusman RM, Chesebro JH, Comerota A, et al. Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection. Clin Cardiol 1999;22:559-73
19. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003;26:3333-41